IDP-023

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Near Add Your Location

Sorting 10 by

Sarah Cannon Research Institute
TriStar Centennial Medical Center
Nashville, TN
  • Accepting patients
MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients
Valkyrie Clinical Trials
Los Angeles, CA
  • Accepting patients
Lifespan Rhode Island Hospital
Providence, RI
  • Accepting patients
University Hospitals Seidman Cancer Center
Seidman Cancer Center at UH Case Medical
Cleveland, OH
  • Accepting patients
Winship Cancer Institute
Emory University
Atlanta, GA
  • Accepting patients
Virginia Cancer Specialists
Fairfax, VA
  • Accepting patients
Weill Cornell
New York, NY
  • Accepting patients
  • Show Principal Investigator

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.